Clinical Trials Logo

Psychedelic Experiences clinical trials

View clinical trials related to Psychedelic Experiences.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06450210 Not yet recruiting - Clinical trials for Psychedelic Experiences

Safety for Home Administration of Microdose Psilocybin Use

Start date: June 2024
Phase: Phase 1
Study type: Interventional

The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants. Eligible participants will be given ascending doses of psilocybin trihydrate and a single, interspersed, randomized placebo on separate days in single-blind fashion. The participants will be asked to complete questionnaires and undergo safety assessments.

NCT ID: NCT05866471 Not yet recruiting - Healthy Clinical Trials

Pairing Psilocybin With Transcutaneous Auricular Vagus Nerve Stimulation

ENHANCE
Start date: August 2024
Phase: Phase 1
Study type: Interventional

This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a known inducer of neuroplasticity and enhanced memory formation, will enhance the long-term beneficial behavioral effects of psilocybin when compared to sham taVNS by allowing memory for insights gained during the psychedelic experience to remain vivid after they will have faded in subjects who receive psilocybin followed by sham taVNS.

NCT ID: NCT05468047 Not yet recruiting - Clinical trials for Psychedelic Experiences

Ketamine Therapy Experiential Education Study

KTEES1
Start date: September 2022
Phase: Early Phase 1
Study type: Interventional

This study investigates the use of low-dose (0.5-0.75 mg/kg; maximum dose of 60 mg regardless of body weight) ketamine hydrochloride injection, USP administered intramuscularly to healthy clinicians as part of an experiential learning practice within a psychedelic-assisted therapy (PAT) training program. The primary objective of this study is to test the hypothesis that competencies required for mental healthcare professionals providing PAT are enhanced by undergoing a single ketamine-assisted therapy experience, as part of a PAT training program. Primary outcomes of this study are self-reported measures of therapeutic efficacy and competency for providing both general and psychedelic-assisted therapy, measured at baseline and four weeks following an academic in-person retreat with optional ketamine administration. Secondary endpoints include measures of personality and magnitude of perceived mystical experiences. Individual changes in scores across time will be calculated, and differences in therapeutic efficacy and competency between clinician trainees who choose to participate in a personal ketamine-assisted therapy session and those who do not will be assessed.